Eyegate Pharmaceuticals (EYEG) Given a $3.00 Price Target at HC Wainwright
Eyegate Pharmaceuticals (NASDAQ:EYEG) has been assigned a $3.00 target price by research analysts at HC Wainwright in a research report issued to clients and investors on Sunday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 424.75% from the company’s previous close.
Separately, ValuEngine upgraded shares of Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Eyegate Pharmaceuticals (NASDAQ EYEG) opened at $0.57 on Friday. Eyegate Pharmaceuticals has a twelve month low of $0.49 and a twelve month high of $2.85. The stock has a market cap of $9.87, a price-to-earnings ratio of -0.61 and a beta of 3.37.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.